Mikhail Blagosklonny is an oncology professor at the New York based Roswell Park Cancer Institute. As a scientist, Mikhail Blagosklonny focusses his research on aging and cancer. He is known for his aging and rapamycin research on life longevity. In his studies, he has proposed the use of the drug to extend the lives of cancer patients by exploiting the likely function of TOR-Signaling in aging process. Mikhail Blagosklonny research has been used in studies regarding anti-aging drugs, the mechanism behind aging as well as cancer therapies aimed at protecting normal cells from damage.
Education and Career Background
Before he joined Roswell Park Cancer Institute as a professor, Mikhail Blagosklonny was a researcher at Ordway Research Institute, a position he held for about 7 years. Mikhail Blagosklonny joined New York Medical College in 2002 right after finishing doctorate in cardiology and experimental medicine at St. Petersburg’s First Pavlov State Medical University, where he had also obtained his M.D. in internal medicine.
Dr. Mikhail Blagosklonny is regular contributor in the world of scientific research and in particular, oncology. He has over 300 research articles to his name, he has written book chapters and done the review of multiple studies on gettingstronger.org. He currently is the associate editor for PLOS ONE, The American Journal of Pathology, International Journal of Cancer, Cell Death and Differentiation, Cancer Research, Autophagy, Therapy and cancer biology. He cofounded Oncoscience, Oncotarget and Aging Journals which he also happens to be co-editor in chief. He is also the chief editor of Cell Cycle. He formulated the cell cyclotherapy and chemotherapeutic engineering approaches towards cancer treatment. He authored a theory on the mechanism behind the aging process referred to as the hyper-function theory on impactjournals.com. His scientific circle of interests is spread over a variety of medical disciplines including apoptosis, mitosis, cell cycle, signal transduction, tumor suppressors and oncogenes among other clinical studies involving cellular and biology molecular.
Aging and Anti-Cancer Research
His lifelong pursuit of a cure for cancer has propelled him towards the exploitation of cancer cells and turn them to anti-cancer strategies through the use of basic science. He has proposed the use of anti-aging drug, rapamycin, against cancer. His interests on impactjournals.com in a cure for cancer have since overlapped with his studies on the aging process. He turns the drug-resisting nature of cancer and its cell cycling process towards the preservation of normal healthy human cells, applicable to both cancer and aging.